title: Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
abstract: Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation.
authors.affiliation: Dept. of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Tueger
authors.forename: F E
authors.initials: FE
authors.lastname: Chen
authors.forename: G
authors.initials: G
authors.lastname: Ahsan
authors.forename: V
authors.initials: V
authors.lastname: McDonald
authors.forename: V E
authors.initials: VE
authors.lastname: Andrews
authors.forename: J A
authors.initials: JA
authors.lastname: Madrigal
authors.forename: M A
authors.initials: MA
authors.lastname: Kazmi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D011859:Radiography; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide